At what enterprise value was MIR - MEDICAL INTERNATIONAL RESEARCH acquired in 2025?

You can find the full valuation details of MIR - MEDICAL INTERNATIONAL RESEARCH on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of MIR - MEDICAL INTERNATIONAL RESEARCH when it was acquired by QUADRIVIO GROUP?

The exact EV/EBITDA multiple for MIR - MEDICAL INTERNATIONAL RESEARCH is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

What was the revenue of MIR - MEDICAL INTERNATIONAL RESEARCH at the time of the deal?

The revenue of MIR - MEDICAL INTERNATIONAL RESEARCH at the time of the deal is estimated to be in the range of 10M - 30M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the MIR - MEDICAL INTERNATIONAL RESEARCH acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the MIR - MEDICAL INTERNATIONAL RESEARCH deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.quadriviogroup.com/fr/media/communiques-de-presse/silver-economy-fund-acquiert-100-de-mir

← DATABASE

Home Database Healthcare & PharmaMIR - MEDICAL INTERNATIONAL RESEARCH

01/2025

MIR - MEDICAL INTERNATIONAL RESEARCH acquired by QUADRIVIO GROUP

ITALY Life Sciences / Medical Devices / Diagnostic Equipment REV 10M - 30M EUR

Context

The secondary buyout of 100% of Medical International Research by Quadrivio Group triggers the complete exit of the incumbent private equity sponsor Aksìa SGR. This ownership transition follows an operational phase marked by an annualized revenue expansion and the successful launch of subscription-based software services. The secondary transaction alters the capital structure to support a broader consolidation strategy amid rising global demand for decentralized respiratory diagnostics. The incoming capital is structured to fund geographic expansion into historically underpenetrated, highly solvent Northern European healthcare jurisdictions including Germany and the United Kingdom. Institutional debt backing for the buyout combines a super-senior revolving credit line with a private unitranche facility designed to provide immediate funding for strategic add-on acquisitions.

MIR - MEDICAL INTERNATIONAL RESEARCH, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Medical International Research, based in Italy, operates as a manufacturer of respiratory diagnostic equipment used in clinical testing and outpatient monitoring. The product infrastructure consists of high-precision spirometers and oximeters paired with single-use disposable respiratory turbines. The primary revenue mechanism relies on the non-discretionary, continuous replacement cycle of these high-margin consumables required to execute every clinical breath measurement. This transactional dependency at the point of care generates predictable recurring turnover directly linked to patient diagnostic volumes. Client retention is highly protected by strict technological lock-in, as closed-source proprietary software applications are vertically embedded into the physical hardware. This architectural barrier effectively stops hardware substitution by third-party generic components and forces institutional clients to absorb high switching costs. The market position is structurally defended by a comprehensive international portfolio of patents covering proprietary flow-sensing designs. Commercial execution is globally insulated by complex regulatory clearances across multiple jurisdictions, including the US FDA, Chinese NMPA, and Brazilian ANVISA. These demanding medical certifications impose high capital entry barriers, protecting the firm against low-cost manufacturing competition.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
02/2025	NOVONESIS	FEED ENZYME ALLIANCE	DENMARK	Life Sciences	This transaction is a strategic corporate carve-out and vertical integration wherein Novonesis fully acquires the sales and distribution activities of the Feed Enzyme Alliance from its long-term joint venture partner, dsm-firmenich
02/2025	EURAZEO / TURENNE CAPITAL / KURMA PARTNERS	GERMITEC	FRANCE	Life Sciences	Germitec raised EUR29 million in a Series B round led by Eurazeo to accelerate its commercial expansion in the United States. The company recently achieved a major regulatory milestone by obtaining FDA "De Novo" clearance in September 2024
12/2024	NEXTSTAGE / IK PARTNERS	EUROBIO SCIENTIFIC	FRANCE	Life Sciences	EB Development (Consortium: NextStage AM & IK Partners) has successfully concluded its takeover bid for Eurobio Scientific, following the results of a reopened offer period. The consortium now holds 88
12/2024	UI INVESTISSEMENT	DIDACTIC	FRANCE	Life Sciences	Didactic reorganized its shareholder base to accelerate its transformation into a European industrial leader. GENEO Capital Entrepreneur and UI Investissement acquired a majority stake, taking over from the previous sponsor
11/2024	NAXICAP PARTNERS	GLOBAL D	FRANCE	Life Sciences	Naxicap Partners has acquired a majority stake (over 60%) in Global D, marking the company’s first independent LBO following its carve-out from the Menix Group. The remaining capital is held by a dozen managers led by the executive team
10/2024	CLAYTON, DUBILIER & RICE (CD&R)	OPELLA	FRANCE	Life Sciences	Sanofi has announced the sale of 50% of its stake in Opella to the American fund CD&R. Opella Healthcare (formerly Sanofi Consumer Healthcare) is a company specializing in consumer healthcare products
10/2024	KKR / KREFELD	ANJAC BEAUTY & HEALTH	FRANCE	Life Sciences	Anjac reorganized its capital by welcoming KKR and Krefeld as minority shareholders, following a competitive process led by Rothschild & Co. The EUR450M investment allowed the exit of historical partners Andera Partners, Bpifrance, and IDIA
10/2024	BANSK GROUP	PETIQ	UNITED STATES	Life Sciences	Bansk Group completed the acquisition of 100% of PetIQ in an all-cash public-to-private transaction. PetIQ was delisted from Nasdaq upon closing and is now operated as a privately held company, with founder Cord Christensen continuing as CEO
09/2024	AGILENT TECHNOLOGIES	BIOVECTRA	CANADA	Life Sciences	Agilent Technologies has finalized the acquisition of BIOVECTRA, a move designed to fundamentally expand the group's contract development and manufacturing (CDMO) portfolio into fast-growing therapeutic modalities
08/2024	RECURSION PHARMACEUTICALS	EXSCIENTIA	UNITED KINGDOM	Life Sciences	Recursion Pharmaceuticals has entered into a definitive agreement to acquire Exscientia in an all-stock transaction. This strategic move aims to bring together two artificial intelligence-driven drug discovery specialists, creating a comprehensive platform that spans the entire process, from biology to computational chemistry

REFERENCES

Revenue range: 10M - 30M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of MIR - MEDICAL INTERNATIONAL RESEARCH by QUADRIVIO GROUP are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: mir - medical international research

Acquirer: quadrivio group